Human collagen demand Target biomedical and medical aesthetics manufacturers seeking human-identical collagen to enable tissue regeneration, injectable aesthetics, and advanced therapies. Highlight TAM growth from bovine/porcine gaps to human-collagen solutions.

Strategic partnerships Leverage the recent collaboration with Hugel to accelerate market entry. Position co-development opportunities with cosmetic, medical aesthetics, and cell therapy players looking to source reliable bio-identical proteins.

Scaled production Emphasize cell-based platform capable of producing human type I collagen at scale for GMP-like applications. Offer as a supplier for high-quality, consistent proteins to biotech, pharma, and regenerative medicine companies.

North Carolina expansion Capitalize on the new NC facilities to demonstrate near-term supply capabilities and regional bio-manufacturing partnerships. Target biopharma and contract manufacturers seeking local, ethical collagen sourcing.

Market timing Position as a first-m mover in a potentially $100–150B TAM for human collagen. Qualify and engage customers in tissue engineering, gene therapy scaffolds, and cosmetic-product manufacturers pursuing animal-free offerings.